Tenaya Therapeutics Inc
TNYA0.682USD
+0.012+1.76%
Market hours （ET）Quotes delayed by 15 min
111.00MMarket Cap
LossP/E TTM
More Details of Tenaya Therapeutics Inc Company
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Company Info
Ticker SymbolTNYA
Company nameTenaya Therapeutics Inc
IPO dateJul 30, 2021
CEOMr. Faraz Ali
Number of employees97
Security typeOrdinary Share
Fiscal year-endJul 30
Address171 Oyster Point Blvd., Suite 500
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone14158652066
Websitehttps://www.tenayatherapeutics.com/
Ticker SymbolTNYA
IPO dateJul 30, 2021
CEOMr. Faraz Ali
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
97.44K
-3.17%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Dr. R. Sanders (Sandy) Williams, M.D.
Dr. R. Sanders (Sandy) Williams, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. David V. Goeddel, Ph.D.
Dr. David V. Goeddel, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey T. (Jeff) Walsh
Mr. Jeffrey T. (Jeff) Walsh
Independent Director
Independent Director
--
--
Dr. Deepak Srivastava, M.D.
Dr. Deepak Srivastava, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
97.44K
-3.17%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Dr. R. Sanders (Sandy) Williams, M.D.
Dr. R. Sanders (Sandy) Williams, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Column Group LP
30.32%
Empery Asset Management, L.P.
5.37%
Casdin Capital, LLC
4.14%
Woodline Partners LP
3.64%
BlackRock Institutional Trust Company, N.A.
3.05%
Other
53.50%
Shareholders
Shareholders
Proportion
The Column Group LP
30.32%
Empery Asset Management, L.P.
5.37%
Casdin Capital, LLC
4.14%
Woodline Partners LP
3.64%
BlackRock Institutional Trust Company, N.A.
3.05%
Other
53.50%
Shareholder Types
Shareholders
Proportion
Venture Capital
31.83%
Hedge Fund
9.06%
Investment Advisor
9.01%
Investment Advisor/Hedge Fund
8.72%
Individual Investor
0.72%
Research Firm
0.39%
Private Equity
0.28%
Bank and Trust
0.18%
Family Office
0.17%
Other
39.63%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
234
97.94M
60.21%
+33.56M
2025Q1
240
59.62M
37.68%
-6.11M
2024Q4
227
46.66M
58.78%
-21.29M
2024Q3
228
59.37M
75.30%
-7.13M
2024Q2
219
58.72M
74.83%
-7.58M
2024Q1
206
57.55M
73.35%
-12.34M
2023Q4
191
47.88M
70.30%
-10.62M
2023Q3
197
52.92M
79.61%
-6.27M
2023Q2
192
50.82M
77.84%
-5.65M
2023Q1
177
48.22M
74.02%
-17.43M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Column Group LP
49.31M
30.32%
+39.91M
+424.60%
May 07, 2025
Empery Asset Management, L.P.
8.73M
5.37%
+8.73M
--
Mar 31, 2025
Casdin Capital, LLC
6.73M
4.14%
--
--
Mar 31, 2025
Woodline Partners LP
5.92M
3.64%
+5.90M
+30563.25%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.95M
3.05%
-52.13K
-1.04%
Mar 31, 2025
The Vanguard Group, Inc.
4.08M
2.51%
+809.99K
+24.75%
Mar 31, 2025
JP Morgan Asset Management
2.10M
1.29%
-2.67M
-55.99%
Mar 31, 2025
VR Adviser, LLC
1.56M
0.96%
--
--
Mar 31, 2025
Renaissance Technologies LLC
1.54M
0.95%
+1.54M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.38M
0.85%
+106.44K
+8.39%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares UltraPro Russell2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
Fidelity Enhanced Small Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Avantis US Equity ETF
0%
iShares Russell 3000 ETF
0%
ProShares Hedge Replication ETF
0%
View more
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
